GLP‑1 usage and effects
- A growing share of Americans have tried GLP‑1 weight‑loss drugs, changing appetite and eating patterns. - Recent reporting cites around 12% of Americans having used a GLP‑1 medication. - Users report reduced snacking, common side effects like nausea, and concerns about rebound weight when stopping ( ).
About 1 in 8 U.S. adults say they have taken a glucagon-like peptide-1 drug, a sign that medicines like Wegovy and Ozempic are reshaping how many Americans eat. (kff.org) KFF reported in May 2024 that 12% of adults had ever used a GLP-1 agonist and 6% were using one at the time of the poll. The survey tied use to weight loss, diabetes treatment, and prevention of heart attacks or strokes in some adults with heart disease. (kff.org) These drugs mimic a gut hormone released after eating. Harvard Health says that signal helps regulate blood sugar, reduces hunger, and slows digestion, which can leave people full sooner and longer. (health.harvard.edu) That biology shows up in day-to-day eating. Reviews of semaglutide research say GLP-1 medicines suppress appetite and lower food and energy intake, which helps explain why users often report less snacking and smaller meals. (pubmed.ncbi.nlm.nih.gov) The tradeoff is often stomach trouble, especially early in treatment. Wegovy’s prescribing information lists nausea, diarrhea, vomiting, constipation, stomach pain, bloating, belching, and heartburn among the most common side effects. (wegovy.com) Doctors have spent so much time managing those symptoms that a multidisciplinary expert consensus on GLP-1 treatment focused on gastrointestinal adverse events including nausea, vomiting, diarrhea, and constipation. The paper said dose escalation and patient counseling are central to keeping people on therapy. (pmc.ncbi.nlm.nih.gov) Another question is what happens when people stop. In the STEP 1 extension study, adults who discontinued semaglutide regained about two-thirds of the weight they had lost within a year, alongside reversals in some cardiometabolic measures. (pmc.ncbi.nlm.nih.gov) JAMA said in December 2024 that real-world discontinuation rates for glucagon-like peptide-1 receptor agonists run about 50% to 75% at 12 months, even though the drugs are intended for long-term treatment of obesity and diabetes. That leaves insurers, employers, and patients weighing drug costs against the likelihood of long-term use. (jamanetwork.com) The result is a medication class that changes appetite by design, but also changes grocery carts, restaurant orders, and expectations about how long weight-loss treatment lasts. For many patients, the question is no longer whether these drugs work, but how long they can stay on them. (kff.org)
